435 related articles for article (PubMed ID: 24388859)
1. Nanoemulsion strategy for olmesartan medoxomil improves oral absorption and extended antihypertensive activity in hypertensive rats.
Gorain B; Choudhury H; Kundu A; Sarkar L; Karmakar S; Jaisankar P; Pal TK
Colloids Surf B Biointerfaces; 2014 Mar; 115():286-94. PubMed ID: 24388859
[TBL] [Abstract][Full Text] [Related]
2. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview.
Brunner HR
J Hum Hypertens; 2002 May; 16 Suppl 2():S13-6. PubMed ID: 11967728
[TBL] [Abstract][Full Text] [Related]
3. Comparative biodistribution and safety profiling of olmesartan medoxomil oil-in-water oral nanoemulsion.
Gorain B; Choudhury H; Tekade RK; Karan S; Jaisankar P; Pal TK
Regul Toxicol Pharmacol; 2016 Dec; 82():20-31. PubMed ID: 27815174
[TBL] [Abstract][Full Text] [Related]
4. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.
Kusumoto K; Igata H; Ojima M; Tsuboi A; Imanishi M; Yamaguchi F; Sakamoto H; Kuroita T; Kawaguchi N; Nishigaki N; Nagaya H
Eur J Pharmacol; 2011 Nov; 669(1-3):84-93. PubMed ID: 21816148
[TBL] [Abstract][Full Text] [Related]
5. Improvement of cellular uptake, in vitro antitumor activity and sustained release profile with increased bioavailability from a nanoemulsion platform.
Choudhury H; Gorain B; Karmakar S; Biswas E; Dey G; Barik R; Mandal M; Pal TK
Int J Pharm; 2014 Jan; 460(1-2):131-43. PubMed ID: 24239580
[TBL] [Abstract][Full Text] [Related]
6. The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes.
Pugsley MK
Proc West Pharmacol Soc; 2005; 48():35-8. PubMed ID: 16416656
[TBL] [Abstract][Full Text] [Related]
7. Enhanced bioavailability and antihypertensive activity of nisoldipine loaded nanoemulsion: optimization, cytotoxicity and uptake across Caco-2 cell line, pharmacokinetic and pharmacodynamic studies.
Mundada VP; Patel MH; Mundada PK; Sawant KK
Drug Dev Ind Pharm; 2020 Mar; 46(3):376-387. PubMed ID: 32031412
[No Abstract] [Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic profiles of a fixed-dose combination of olmesartan medoxomil and amlodipine in healthy Chinese males and females.
Chen X; Hu P; Jiang J; Liu T; Zhong W; Liu H; Zhao Q
Clin Drug Investig; 2012 Dec; 32(12):783-90. PubMed ID: 23160920
[TBL] [Abstract][Full Text] [Related]
9. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
Dudhipala N; Veerabrahma K
Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287
[TBL] [Abstract][Full Text] [Related]
10. Oil based nanocarrier for improved oral delivery of silymarin: In vitro and in vivo studies.
Parveen R; Baboota S; Ali J; Ahuja A; Vasudev SS; Ahmad S
Int J Pharm; 2011 Jul; 413(1-2):245-53. PubMed ID: 21549187
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of olmesartan medoxomil in the rat monocrotaline model of pulmonary hypertension.
Kato T; Nasu T; Sonoda H; Ito KM; Ikeda M; Ito K
J Cardiovasc Pharmacol; 2008 Jan; 51(1):18-23. PubMed ID: 18209564
[TBL] [Abstract][Full Text] [Related]
12. Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: Performance and mechanism.
Gao F; Zhang Z; Bu H; Huang Y; Gao Z; Shen J; Zhao C; Li Y
J Control Release; 2011 Jan; 149(2):168-74. PubMed ID: 20951749
[TBL] [Abstract][Full Text] [Related]
13. Development of a population pharmacokinetic model to describe olmesartan medoxomil/ hydrochlorothiazide (20/12.5 mg) FDC tablet in male healthy South Korean subjects.
Chae JW; Baek IH; Seo JW; Jung SH; Back HM; Song BJ; Lee BY; Yun HY; Kang W; Kwon KI
Int J Clin Pharmacol Ther; 2014 Aug; 52(8):676-83. PubMed ID: 24849193
[TBL] [Abstract][Full Text] [Related]
14. Can the pharmacokinetic characteristics of olmesartan medoxomil contribute to the improvement of blood pressure control?
Wehling M
Clin Ther; 2004; 26 Suppl A():A21-7. PubMed ID: 15291376
[TBL] [Abstract][Full Text] [Related]
15. Olmesartan/amlodipine: blood pressure lowering and beyond in special populations.
Erdine S
Ther Adv Cardiovasc Dis; 2012 Feb; 6(1):31-44. PubMed ID: 22222315
[TBL] [Abstract][Full Text] [Related]
16. Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update.
Chrysant SG; Dimas B; Shiraz M
J Hum Hypertens; 2007 Sep; 21(9):699-708. PubMed ID: 17554345
[TBL] [Abstract][Full Text] [Related]
17. Development and bioavailability assessment of ramipril nanoemulsion formulation.
Shafiq S; Shakeel F; Talegaonkar S; Ahmad FJ; Khar RK; Ali M
Eur J Pharm Biopharm; 2007 May; 66(2):227-43. PubMed ID: 17127045
[TBL] [Abstract][Full Text] [Related]
18. Olmesartan medoxomil: the seventh angiotensin receptor antagonist.
Gardner SF; Franks AM
Ann Pharmacother; 2003 Jan; 37(1):99-105. PubMed ID: 12503943
[TBL] [Abstract][Full Text] [Related]
19. In situ intestinal permeability and in vivo absorption characteristics of olmesartan medoxomil in self-microemulsifying drug delivery system.
Kang MJ; Kim HS; Jeon HS; Park JH; Lee BS; Ahn BK; Moon KY; Choi YW
Drug Dev Ind Pharm; 2012 May; 38(5):587-96. PubMed ID: 21988221
[TBL] [Abstract][Full Text] [Related]
20. Olmesartan medoxomil combined with hydrochlorothiazide improves 24-hour blood pressure control in moderate-to-severe hypertension.
Rosenbaum D; Girerd X
Curr Med Res Opin; 2012 Feb; 28(2):179-86. PubMed ID: 22114906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
